Company Overview

Vilin Bio Med Limited was originally incorporated on June 29, 2005, and commenced business on July 11, 2005, as issued by the Registrar of Companies, Andhra Pradesh, Hyderabad. The Company is engaged in the domestic business of manufacturing pharmaceutical products. Incorporated in 2005, Vilin Bio Med Ltd operates in the business of manufacturing and selling pharmaceutical products. As an ISO-9001-2008 and GMP-certified organization, it adheres to strict quality protocols, ensuring that its products are safe, effective, and reliable.

At present, the Company is engaged in the domestic manufacturing of Pharmaceuticals products. The manufacturing unit is located in Roorkee, in the State of Uttarakhand. The company has established itself as a distinguished manufacturer in the pharmaceutical sector, focusing on quality production and compliance with international standards.

Financial Performance and Market Position

The company's financial position as of March 28, 2025, reflects its market standing. As of Mar 28, 2025, 03:40 PM, the market cap of Vilin Bio Med Ltd stood at Rs. 28.46 Cr. Vilin Bio Med Ltd has an operating revenue of Rs. 51.05 Cr. on a trailing twelve-month (TTM) basis.

The company has shown an impressive annual revenue growth of 31%, which is outstanding. However, its pre-tax margin of 1% needs improvement, and its Return on Equity (ROE) of 0% is poor and requires attention. The company maintains a reasonable debt-to-equity ratio of 1%, which signals a healthy balance sheet.

Key Financial Metrics

- Market Capitalization: ₹28.46 Crores (as of March 28, 2025)

- Operating Revenue: ₹51.05 Crores (TTM basis)

- Annual Revenue Growth: 31%

- Pre-Tax Margin: 1%

- ROE: 0%

- Debt to Equity: 1%

- PE Ratio: 170.00 (as of March 28, 2025)

- PB Ratio: 0.80 (as of March 28, 2025)

- Promoter Holding: 63.9%

Business Operations and Product Portfolio

The major products for manufacturing dosage forms consist of Oral Liquid (Syrups/Suspensions/Dry Powders - Beta & Non-Beta Lactam), Tablets & Capsules (Beta & Non-Beta Lactam), and External Preparations. It sells its products in bulk to Pharmaceuticals Manufacturers, Marketers, and Traders. Its product categories include solid oral dosage forms (beta and non-beta-lactam), oral liquids, external preparations, and dry powders.

The company's product range includes various therapeutic formulations such as Cefixime, Azithromycin, Sulbmticilline, Aceclofenac, Citicolin Sodium, Metformine, Pregabaline, Gabapentin, Diclofenac Sodium, Thiocolchicoside, Linseed Oil, Menthol, and Methyl Salicylate, among others. Its external preparations include ointments, creams, lotions, gels, and pastes, primarily designed for topical application.

Its beta-lactam products are used to treat infections caused by certain bacteria and parasites. Its non-beta-lactam tablets and capsule products are generally used for common ailments like colds, flu, fever, anti-gastrological, antimalarial, and various other viral diseases.

Manufacturing Capabilities and Quality Standards

The company is committed to quality and innovation, employing a skilled workforce of over 600 professionals who ensure rigorous quality control. The company operates from its manufacturing facility in Uttarakhand, ensuring compliance with pharmaceutical manufacturing standards and regulatory requirements.

Vilin Bio Med Limited continues to focus on expanding its market presence while maintaining its commitment to quality pharmaceutical manufacturing. The company's strategic positioning in the growing pharmaceutical sector, combined with its established manufacturing capabilities and product portfolio diversification, positions it as a notable player in the domestic pharmaceutical manufacturing space.

Growth Timeline and Expansion

The company has demonstrated consistent growth since its inception.

- 2006: Started its first commercial production.

- 2007: Expanded Phase 2 for Beta Lactam facility (16,000 sq ft) for Tablet, Capsule, and Dry Syrup sections.

- 2010: Acquired over 1000 molecules Drug Approvals with different strengths in therapeutic areas of Diabetic, Neuro, and Cardio.

- 2014: Added the Sachet section in the Non-Beta Lactum facility.

IPO and Public Listing

The Company completed its Initial Public Offering (IPO) by allotting a fresh issue of 40,00,000 Equity Shares of Rs 10/- each, raising funds aggregating to Rs 12 Crore on June 7, 2023. The shares were listed on the NSE SME on June 30, 2023. The Vilin Bio Med IPO price was ₹30 per share.

Stock Performance and Valuation

The 52-week high for Vilin Bio Med Ltd's share price is Rs. 27.70, while the 52-week low is Rs. 15.40. The stock is traded on both NSE and BSE exchanges.

- BSE Code: 78871

- NSE Symbol: VILINBIO

- ISIN: INE0L4V01013

Vilin Bio Med Ltd has given a return of 9.09% in the last 1 year. As per Value Research classification, it is a Small Cap company. Please note that this is a thinly traded stock.

Management and Corporate Governance

The company maintains a professional management structure with designated key personnel overseeing operations. The Chairman of the company is [Chairman's Name - Placeholder], and the Managing Director is Viswa Prasad Sadhanala. In the main management, [Chairman's Name - Placeholder] serves as Chairman, and Ashdeep Kaur is the Company Secretary for Vilin Bio Med Ltd.

Vilin Bio Med Ltd's stock represents an opportunity within India's pharmaceutical manufacturing sector, underpinned by its manufacturing capabilities and product portfolio. However, investors should carefully consider the company's financial metrics, market position, and the characteristics of a thinly traded stock.